AUTHOR INDEX

Volume 61 • 1993

Abe, A. *See* Mitsui, M.
Abe, K. and Saito, H.
Hippocampal NMDA synaptic potential 333
Achiha, M., nee Hara *See* Amano, M.
Adachi-Akahane, S., Amano, Y., Okuyama, R. and Nagao, T.
Quaternary diltiazem on ventricular cells 263
Agata, M. *See* Inukai, S.
Aibara, S., Mori, Mikiko, Iwamoto, T., Tsubokawa, M., Takamori, H. and Tsukada, W.
Anti-allergic actions of DS-4574 267
Akaike, A. *See* Ujihara, H.
Akaike, A., Sasa, M., Tamura, Y., Ujihara, H. and Takaori, S.
Muscarinic excitation of chromaffin cells 145
Amano, M., Goto, A., Sakai, A., Achiha, M., nee Hara, Takahashi, N., Hara, C. and Ogawa, Nobuya
Anticonflict effects of buspirone and 1-PP 311
Amano, M., Goto, A., Takahashi, N., Hasegawa, Takaaki and Nabeshima, T.
Anti-anoxic effects of BMY-21502 157
Amano, Y. *See* Adachi-Akahane, S.
Arakawa, T., Fukuda, T., Higuchi, K., Koike, K., Satoh, H. and Kobayashi, K.
Proton-pump inhibitor and cytoprotection 299
Asai, Y. *See* Umemura, K.

Chen, C.-F. *See* Hsieh, M.-T.
Chiba, S. *See* Fujiwara, T.
Chiba, Y. *See* Misawa, M.

Dey, S.K. *See* Kogo, H.

Ebihara, A. *See* Fujimura, A.
Egashira, T. *See* Goto, S.

Fujimori, K. *See* Watano, T.
Fujimori, T. *See* Nomoto, K.
Fujimura, A., Shiga, T., Ohashi, K. and Ebihara, A.
Chronopharmacology of FK506 137
Fujita, T. *See* Uchihashi, Y.
Fujiwara, M. *See* Kitagawa, S.
—— *See* Yamaguchi, Y.
Fujiwara, T. and Chiba, S.
α-Adrenoceptors in rabbit arteries 171
Fukata, Y. *See* Ogawa, Nobuyuki
Fukuda, T. *See* Arakawa, T.
Fukushima, H. *See* Ogawa, Nobuyuki

Gong, D.-W. *See* Ozawa, S.
Goto, A. *See* Amano, M.
Goto, M. *See* Inukai, S.
Goto, S., Egashira, T. and Yamanaka, Y.
Serotonin-uptake modulators in human CSF 51

Hara, C. *See* Amano, M.
—— *See* Ogawa, Nobuya
Hara, H., Yokota, K., Shimazawa, M. and Sukamoto, T.
Ca antagonists and glutamate toxicity 361
Hasegawa, Takaaki *See* Amano, M.
Hasegawa, Takashi, Yokotani, K., Okuma, Y., Manabe, M., Hirakawa, M. and Osumi, Y.
Central α-CGRP and noradrenaline overflow 325
Hayashi, A. *See* Oyama, Y.
Hayashi, K. *See* Ogawa, S.
Hayashi, M. *See* Naraba, H.
Higuchi, K. *See* Arakawa, T.
Hirakawa, M. *See* Hasegawa, Takashi
Hirata, Y. *See* Umemura, K.
Honda, K. *See* Yazawa, H.
Honda, Y. *See* Ujihara, H.
Hori, M. *See* Kwon, S.-C.
Hsieh. C.-C. *See* Hsieh, M.-T.
Hsieh, M.-T., Su, S.-H., Tsai, H.-Y., Peng, W.-H., Hsieh, C.-C. and Chen, C.-F.
Palmatine on locomotion and monoamine 1

Ikizawa, K. *See* Yanagihara, Y.
Imai, Y. *See* Naraba, H.
Imaizumi, N. *See* Kitagawa, S.
—— *See* Yamaguchi, Y.
Inoue, K. *See* Watano, T.
Inukai, S., Agata, M., Sato, M., Naitou, A., Matsukawa, H. and Goto, M.
Novel aldose reductase inhibitor, TAT 221
Ishida, R. *See* Ogiku, N.
Ishii, K. *See* Yamagishi, T.
Ito, K. *See* Miyamoto, A.
Iwamoto, T. *See* Aibara, S.

Jinno, Y. *See* Ogawa, Nobuyuki
Johnson, D.C. *See* Kogo, H.

Kameyama, T. *See* Ogawa, S.
Kamiya, T. *See* Mori, Mayumi
Kanaoka, S. *See* Watanabe, K.
Kaneta, S. *See* Ogawa, Nobuyuki
Kaneto, H. *See* Tokuyama, S.
Karaki, H. *See* Kwon, S.-C.
—— *See* Mitsui, M.
Karasawa, A. *See* Mizumoto, H.
Kashii, S. *See* Ujihara, H.
Kato, R. *See* Ozawa, S.
Kato, S. *See* Takeuchi, K.
Katoh, T. *See* Takahashi, Masanori
Kawano, E. *See* Ohoi, I.
Kinami, J., Tsuchihashi, H., Maruyama, K., Sasaki, K. and Nagatomo, T.
Nipradilol and α_1-adrenoceptor subtypes 81
Kiniwa, M. *See* Yanagihara, Y.
Kitagawa, S. *See* Yamaguchi, Y.
Kitagawa, S., Yamaguchi, Y., Kunitomo, M., Imaizumi, N. and Fujiwara, M.
Vasoconstriction in arteriosclerosis 283
Kitaichi, K. *See* Sakamoto, O.
Kobayashi, H. *See* Nomoto, K.
Kobayashi, K. *See* Arakawa, T.
Koda, A. *See* Sakamoto, O.
—— *See* Yanagihara, Y.
Kogo, H., Johnson, D.C., Dey, S.K. and Takeo, S.
Catechol estradiol and uterine ODC activity 65
Kogushi, M. *See* Nomoto, K.

Koike, H., Saito, H. and Matsuki, N.
Block of N-type Ca channel by aniracetam 277
Koike, K. *See* Arakawa, T.
Kojima, K. *See* Takahashi, Masanori
Kubota, K. *See* Takahashi, Masanori
Kunitomo, M. *See* Kitagawa, S.
—— *See* Yamaguchi, Y.
Kurebayashi, Y. *See* Tabuchi, Y.
Kuribara, H. *See* Uchihashi, Y.
Kwon, S.-C., Ozaki, H., Hori, M. and Karaki, H.
Isoproterenol on myoplasmic Ca^{2+} in taenia 57

Manabe, M. *See* Hasegawa, Takashi
Maruyama, K. *See* Kinami, J.
Masukawa, T. and Tochino, Y.
Circadian rhythm in resistance to hypoxia 197
Matsuda, T. *See* Mori, Mayumi
Matsukawa, H. *See* Inukai, S.
Matsuki, N. *See* Koike, H.
Matsumoto, Y. *See* Tanimura, A.
Matsuura, N. *See* Yanagihara, Y.
Minamide, S. *See* Ogiku, N.
Misawa, M. and Chiba, Y.
Airway hyperresponsiveness in rats 41
Mitsui, M., Abe, A., Tajimi, M. and Karaki, H.
Fura-2 leakage in smooth muscle 165
Miwa, A. *See* Ogawa, Nobuyuki
Miyamoto, A., Ito, K. and Nishio, A.
β-Adrenoceptors in pig basilar artery 93
Mizumoto, H. and Karasawa, A.
Adenosine A_1-receptor antagonist 251
Mori, A. *See* Shiraishi, S.
Mori, H. *See* Sakamoto, O.
Mori, Mayumi *See* Watano, T.
Mori, Mayumi, Kamiya, T., Tsushima, H. and Matsuda, T.
ACh release in the hypothalamus 203
Mori, Mikiko *See* Aibara, S.
Morita, T. *See* Uchihashi, Y.

Nabeshima, T. *See* Amano, M.
—— *See* Ogawa, S.
Nagao, T. *See* Adachi-Akahane, S.
Nagata, K. *See* Ozawa, S.
Nagatomo, T. *See* Kinami, J.
Naitou, A. *See* Inukai, S.
Nakamura, K. *See* Ohoi, I.
Nakashima, M. *See* Umemura, K.
Nakazawa, K. *See* Watano, T.
Naraba, H., Imai, Y., Hayashi, M. and Oh-ishi, S.
Enhancement of PAF production 109
Nishio, A. *See* Miyamoto, A.
Nomoto, K., Saeki, T., Kogushi, M., Kobayashi, H.,
Fujimori, T. and Yamatsu, I.
E5510 on growth factor release 7

Obama, T. *See* Watano, T.
Ogawa, Nobuya *See* Amano, M.
Ogawa, Nobuya, Hara, C. and Takaki, S.
Novel anxiolytic SC-48274 115
Ogawa, Nobuyuki, Fukata, Y., Kaneta, S., Jinno, Y., Miwa, A. and Fukushima, H.
KRN2391 and mesenteric artery 303
Ogawa, S., Nabeshima, T., Kameyama, T. and Hayashi, K.
NGF ameliorates amnesia in rats 141
Ogihara, Y. and Okabe, S.
Mechanism underlying delayed ulcer healing 123
Prednisolone in ulcer healing 133
Ogiku, N., Sumikawa, H., Minamide, S. and Ishida, R.
Effect of imidapril on SHRSP 69
Oh-ishi, S. *See* Naraba, H.
Ohashi, K. *See* Fujimura, A.
Ohoi, I., Sone, K., Tobari, H., Kawano, E. and Nakamura, K.
Measurement of oxygen free radicals 101
Ohuchi, T. *See* Takeuchi, K.
Okabe, S. *See* Ogihara, Y.
—— *See* Takeuchi, K.
Okamoto, K. *See* Sakuta, H.
Okuma, Y. *See* Hasegawa, Takashi
Okuyama, R. *See* Adachi-Akahane, S.
Osumi, Y. *See* Hasegawa, Takashi
Oyama, Y., Hayashi, A. and Ueha, T.
Ginkgo biloba on Ca^{2+}-induced oxidation 367
Ozaki, H. *See* Kwon, S.-C.
Ozawa, S., Nagata, K., Gong, D.-W., Yamazoe, Y. and Kato, R.
Expression of arylsulfotransferase cDNA 153

Peng, W.-H. *See* Hsieh, M.-T.

Saeki, T. *See* Nomoto, K.
Saito, H. *See* Abe, K.
—— *See* Koike, H.
Sakai, A. *See* Amano, M.
Sakamoto, O., Mori, H., Kitaichi, K. and Koda, A.
Low immunosuppressive fluoropyrimidines 209
Sakuta, H., Okamoto, K. and Watanabe, Y.
K^+ current and cGMP 259
Sasa, M. *See* Akaike, A.
—— *See* Ujihara, H.
Sasaki, K. *See* Kinami, J.
Sato, M. *See* Inukai, S.
Satoh, H. *See* Arakawa, T.
Shida, T. *See* Yanagihara, Y.
Shiga, T. *See* Fujimura, A.
Shima, S.
Adrenergic receptors of seminal vesicle 87
Shimazawa, M. *See* Hara, H.
Shiraishi, S., Mori, A. and Toda, N.
Internal thoracic artery response 243
Sone, K. *See* Ohoi, I.
Su, S.-H. *See* Hsieh, M.-T.
Sugaya, K. *See* Takahashi, Masanori
Sukamoto, T. *See* Hara, H.
Sumikawa, H. *See* Ogiku, N.

Tabuchi, Y. and Kurebayashi, Y.
Antisecretory effect of ebselen 255
Taira, N. *See* Yamagishi, T.
Tajimi, M. *See* Mitsui, M.
Takahashi, Masakatsu *See* Tokuyama, S.
Takahashi, Masanori, Sugaya, K., Kojima, K., Katoh, T., Ueki, M. and Kubota, K.
SUT-8701 prevents cholinergic degeneration 341
Takahashi, N. *See* Amano, M.
Takaki, S. *See* Ogawa, Nobuya
Takamori, H. *See* Aibara, S.
Takanaka, A. *See* Watano, T.
Takaori, S. *See* Akaike, A.
Takasugi, N.
Calcium-induced vasodilation 177
Takeo, S. *See* Kogo, H.
Takeuchi, K., Ohuchi, T., Kato, S. and Okabe, S.
Gastric protection by L-arginine 13

Tamura, Y. *See* Akaike, A.
—— *See* Ujihara, H.
Tanimura, A., Tojyo, Y. and Matsumoto, Y.
Cytosolic pH and Ca^{2+} in parotid cells 357
Teramoto, N.
Semotiadil on I_{Ca} of rabbit portal vein 183
Tobari, H. *See* Ohoi, I.
Tochino, Y. *See* Masukawa, T.
Toda, N. *See* Shiraishi, S.
Tojyo, Y. *See* Tanimura, A.
Tokuyama, S., Takahashi, Masakatsu and Kaneto, H.
5-HT mediated systems in PSY-SIA 237
Tsai, H.-Y. *See* Hsieh, M.-T.
Tsubokawa, M. *See* Aibara, S.
Tsuchihashi, H. *See* Kinami, J.
Tsukada, W. *See* Aibara, S.
Tsushima, H. *See* Mori, Mayumi

Uchihashi, Y., Kuribara, H., Morita, T. and Fujita, T.
Repeated administration of ketamine 149
Ueha, T. *See* Oyama, Y.
Ueki, M. *See* Takahashi, Masanori
Uematsu, T. *See* Umemura, K.
Ujihara, H. *See* Akaike, A.
Ujihara, H., Akaike, A., Tamura, Y., Yokota, T., Sasa, M., Kashii, S. and Honda, Y.
Nitroprusside on retinal NMDA receptor 375
Umemura, K., Asai, Y., Hirata, Y., Uematsu, T. and Nakashima, M.
Effect of ibudilast in the inner ear 75

Watanabe, K., Yano, S., Yamamoto, M. and Kanaoka, S.
Histamine and acid secretion in mice 229
Watanabe, Y. *See* Sakuta, H.
Watano, T., Nakazawa, K., Obama, T., Mori, Mayumi, Inoue, K., Fujimori, K. and Takanaka, A.
Hirsuteine and dopamine release 351

Yamagishi, T., Ishii, K. and Taira, N.
Class III agents on cloned K channels 371
Yamaguchi, Y. *See* Kitagawa, S.
Yamaguchi, Y., Kitagawa, S., Imaizumi, N., Kunitomo, M. and Fujiwara, M.
Cholesterol loading on MRL-*lpr/lpr* mice 291
Yamamoto, M. *See* Watanabe, K.
Yamanaka, Y. *See* Goto, S.
Yamatsu, I. *See* Nomoto, K.
Yamaya, H. *See* Yanagihara, Y.
Yamazoe, Y. *See* Ozawa, S.
Yanagihara, Y., Kiniwa, M., Ikizawa, K., Shida, T., Matsuura, N. and Koda, A.
IPD-1151T on human IgE production 31
Yanagihara, Y., Kiniwa, M., Ikizawa, K., Yamaya, H., Shida, T., Matsuura, N. and Koda, A.
IPD-1151T on murine IgE production 23
Yano, S. *See* Watanabe, K.
Yazawa, H. and Honda, K.
M_3-muscarinic receptor in rat prostate 319
Yokota, K. *See* Hara, H.
Yokota, T. *See* Ujihara, H.
Yokotani, K. *See* Hasegawa, Takashi

SUBJECT INDEX

Volume 61 • 1993

Acetoxymethyl ester of fura-2 165
Acetylcholine release 203, 341
Adenosine A_1-receptor antagonist 251
Adrenal medulla 145
Adrenergic receptor 87
α_1-Adrenoceptor (dominant) 171
α_1-Adrenoceptor subtype 81
β_1-Adrenoceptor 93
Aging 319
Aldose reductase inhibitor 221
Allergy (types I–IV) 267
Alzheimer's disease 341
Ambulatory activity 149
Aniracetam 277
Anti-allergic action 267
Anti-anoxic effect 157
Antiarrhythmic agent (class III) 371
Anticonflict effect 311
Antidepressant (endogenous) 51
Anti-inflammatory action 267
Anxiety 115
Arginine 13
Arteriosclerosis 283
Arylsulfotransferase (ST1A1) 153
Asthma (allergic) 41
Autoimmune 291

Basilar artery (pig) 93
Biological parameter (renal function) 69
α_1- and β-Blocking activity 81
Blood glucose 197
BMY-21502 (1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone) 157
Body temperature 197
Brain (monkey) 51
Bronchoconstriction 41
Buspirone 115, 237, 311

Ca^{2+} (cytosolic) 57, 357
Ca^{2+} antagonist 183, 361
Ca^{2+} current 183
Ca^{2+} channel (L-type) 263
Ca^{2+} channel (voltage-gated) 277
Ca^{2+} loading 367
Calcification 283
α-Calcitonin gene-related peptide 325
Cannula inserting method 171
Cell proliferation 7
Cerebrospinal fluid (human) 51
Chemiluminescence 101
Cholecystokinin octapeptide (CCK8) 341
Cholesterol deposition (aortic) 291
Choline acetyltransferase (CAT) 141, 341
Cholinergic regulation 87
Chronopharmacology 137
Circadian rhythm 197
Communication box 115, 237
Connective tissue 123
ω-Conotoxin 277
Contractile response 283
Contraction of ulcer base 123
Coronary artery 243
Cromakalim 303
Cyclic AMP 57
Cyclic GMP 259
Cytoprotection 13, 299

Delayed type hypersensitivity 209
Delayed-healing 123
Dentate gyrus 333
Diabetic neuropathy 221
Diazepam 115, 311
[^{3}H]-Dihydroalprenolol 93
Diuretic effect 251
Dopamine release 351
DS-4574 (6-(2-cyclohexylethyl)-[1,3,4]thiadiazolo[3,2-*a*]-1,2,3-triazolo[4,5-*d*]pyrimidin-9 (3*H*)-one) 267

E5510 (4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid) 7
Ear (rabbit) 177
Ebselen 255
Endothelium-derived relaxing factor (EDRF) 243
Epalrestat 221
Erythrocyte (sheep) 209
Estradiol 65
Ethanol damage 299

Fibroplasia 133
FK 506 137
5-Fluoropyrimidine derivatives (UK-21 and UK-25) 209
Fura-2 165

Gastric acid secretion 229, 255
Gastric lesion 13
Gastric mucosa 299
Gastric ulcer 255
Ginkgo biloba extract 367
Glibenclamide 259

Hearing disturbance 75
High-cholesterol diet 283
Hirsuteine 351
Histamine 229
Histamine H_2-antagonist 229
2- and 4-Hydroxyestradiol 65
Hypercholesterolemia 291
Hyperresponsiveness (airway) 41
Hypothalamus 203, 325

Ibudilast 75
Idebenone 157
IgE production 23, 31
IgE receptor (low affinity) (FcεRII/CD23) 23
Imidapril 69
Immunosuppressant 137
Immunotoxicity 209
Indomethacin 123
Inflammation 41, 267
Interferon-γ 31
Interleukin 4 (IL-4) 23, 31
Interleukin 4 (IL-4) mRNA 31
Internal thoracic artery (ITA) 243
IPD-1151T (suplatast tosilate, (±)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]dimethylsulfonium *p*-toluenesulfonate) 23, 31
Isoproterenol 57

K^+ channel 259
K^+ channel (cloned) 371
Ketamine 149
KRN2391 (*N*-cyano-*N'*-(2-nitroxyethyl)-3-pyridinecarboximidamide monomethanesulfonate) 303
KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine) 251

Locomotion 1
Lyso-platelet-activating factor 109

Merthiolate 109
Mesenteric artery 303
Meth A tumor 209
Mg^{2+} 333
Microdialysis 203
Monoamine concentration 1
Morphine tolerance 237
Motor nerve conduction velocity 221
MRL-*lpr/lpr* mice 291
Muscarinic excitation 145
Muscarinic receptor subtype 203, 319
Myocardium 101

N-methyl-D-aspartate (NMDA) receptor 333, 375
N^G-nitro-L-arginine 177
Nerve growth factor (NGF) 141
Neurotoxicity (glutamate-induced) 361
Nicorandil 303
Nicotinic receptor 351
Nifedipine 303
Nipradilol 81
Nitric oxide (NO) 13, 177, 243
Nitroprusside 375
Nootropic drug 277
Noradrenaline 93, 325
Norepinephrine *See* Noradrenaline

Optical isomer 81
Oxidative metabolism 367
Oxiracetam 157
Oxygen radical 101
Oxygenation 101

Palmatine 1
Paraventricular nucleus 325
Parotid cell (rat) 357
Paroxetine binding 51
Patch-clamp (whole-cell) 277
PC12 cell 351
Peripheral artery (rabbit) 171
pH (cytosolic) 357
Platelet (human) 7
Platelet-activating factor 109
Platelet-derived growth factor 7
Portal vein 183
[^{3}H]-Prazosin 81
Prednisolone 133
Primary cell culture 361
Prostaglandin 13
Prostate (rat) 319
Protein kinase C 145
Proton-pump inhibitor 299
1-(2-Pyrimidinyl)-piperazine (1-PP) 311

Quaternary diltiazem 263

Receptor binding 341
Relaxation 57, 93
Resistance to hypoxia 197
Retina 375
Reverse tolerance 149

SC-48274 ((±)3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione, monohydrochloride) 115
Seminal vesicle 87
Serotonin (5-HT) 237
Serotonin uptake 51
Smooth muscle (intestinal) 57
Smooth muscle cell 7
Sorbitol 221
Stomach (mouse isolated) 229
Stress-induced analgesia (SIA) 237
Stroke-prone spontaneously hypertensive rats (SHRSP) (salt-loaded) 69
Sulfation (dopamine and minoxidil) 153
Sulfotransferase 153
Superoxide dismutase (human, recombinant) 101
Supraoptic nucleus 203
Survival time 197
SUT-8701 (*N*-[(1,1-dimethylethoxy)carbonyl]-*O*-(dimethylphosphinyl)-L-tyrosyl-L-norleucylglycyl-L-tryptophyl-L-norleucyl-L-aspartyl-L-phenylalaninamide) 341
Sympathetic and adrenomedullary system 325
Synaptic potential 333

Thrombosis (inner ear microcirculation, anterior inferior cerebellar) 75
Tracheal smooth muscle 165
Triacsin C 109

Ulcer (acetic acid-induced) 123, 133
Uterine ornithine decarboxylase activity 65

Vagus nerve 229
Vascular bed 177
Vascular smooth muscle 165
Vasodilatation 183
Vasodilation (Ca^{2+}-induced) 177
Ventricular myocyte 263
Vitamin D 283
Vogel's conflict test 311

Water maze 141

Xenopus oocyte 371

Zymosan (opsonized) 109